Source: International Congress 2014 – Intervening in allergic asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Niven, C. Bucknall, R. Chaudhuri, R. Kurukulaaratchy, F. De Iorio, A. Menzies-Gow (Manchester, Glasgow, Southampton, Frimley, London, United Kingdom). Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study. Eur Respir J 2014; 44: Suppl. 58, 3484

Member's Comments

No comment yet.

Related content which might interest you: Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of asthma . A comparative study Source: International Congress 2014 – Asthma: clinical problems Year: 2014 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014